Global Oncology Biosimilars Market
| 出版 | BCC Research |
| 出版年月 | 2026年03月 |
| ページ数 | 173 |
| 価格 | 記載以外のライセンスについてはお問合せください |
| シングルユーザ | USD 4,650.00 |
| 企業ライセンス | USD 8,035.00 |
| 種別 | 英文調査報告書 |
| 商品番号 | SMR-1143611436 |
Report Highlights
The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.
Report Includes
- 140 data tables and 40 additional tables
- In-depth analysis of the global market for oncology biosimilar drugs
- Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.
Report Scope
The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by distribution channel.
Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.
It includes global revenue ($ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.
Report Synopsis
| Report Metrics | Details | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2024 | ||||||||||||||
| Forecast period considered | 2025-2030 | ||||||||||||||
| Base year market size | $8.7 Billion | ||||||||||||||
| Market size forecast | $17.5 Billion | ||||||||||||||
| Growth rate | CAGR of 12.6% from 2025 to 2030 | ||||||||||||||
| Units considered | $ Millions | ||||||||||||||
| Segments covered | By Disease Indication, Drug Class, Route of Administration, Distribution Channel, and Region | ||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America | ||||||||||||||
| Countries covered | U.S., Canada, Mexico, Japan, China, India, Australia, South Korea, Germany, the U.K., France, Italy, Spain, Brazil, Argentina, Rest of Europe, Rest of Asia-Pacific, Rest of South America, the Middle East, and Africa | ||||||||||||||
| Key Market Drivers |
|
||||||||||||||
| Companies studied |
|
Table of Contents
Chapter- 1: Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter- 2: Market Overview
Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Chapter- 3: Market Dynamics
Overview
Market Drivers
Market Restraints
Market Opportunities
Chapter- 4: Regulatory Landscape
Regulatory Framework
Chapter- 5: Emerging Technologies and New Developments
Overview
Emerging Technologies
Patent Analysis
Chapter- 6: Market Segmentation Analysis
Segmentation Breakdown
Global Oncology Biosimilars Market, by Indication
Global Oncology Biosimilars Market, by Drug Class
Global Oncology Biosimilars Market, by Route of Administration
Global Oncology Biosimilars Market, by Distribution Channel
Geographic Breakdown
Global Oncology Biosimilars Market, by Region
Chapter- 7: Competitive Intelligence
Industry Structure
Company Share Analysis for Oncology Biosimilars Market
Strategic Analysis
Chapter- 8: Sustainability in the Oncology Biosimilars Market: ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives of the Oncology Biosimilars Industry
Concluding Remarks
Chapter- 9: Appendix
Methodology
Abbreviations
Company Profiles
Emerging Start-ups/Market Disruptors